included 52 consecutive patients treated for non-metastatic uterine cervical
cancer from August 2011 to April 2021 in this retrospective analysis.
median age of patients was 64 (range, 30-90) years old, and the performance
status (PS) was as follows; PS0: 41, PS1: 10, PS2: 2. All patients had a
histopathological diagnosis of uterine cervical cancer, and 46 patients had
squamous cell carcinoma (SCC), and the remaining 6 had adenocarcinoma. Primary
tumor stages (FIGO) were distributed as follows: IB: 6, IIA: 5, IIB: 12, IIIB:
3, IIIC1:19, IIIC2:4 (with Para-aortic lymph node metastasis), and IVB: 2.
median dose of WPRT and WPRT-CS was 36 (range, 22–43.2) and 14.4 (range, 9–28)
Gy, respectively. Median HDR-ICBT dose/fractions to Point A was 24Gy/5 Fr
(range, 15–30 Gy/3–6Fr).
one patient developed multiple lung metastases during radiation therapy and
terminated local treatment. She was excluded from this analysis.